Is Alexion Pharmaceuticals Inc Poised for Years of Dominance?

Between cost-cutting, earnings gains, and Soliris' huge potential, Alexion could become the darling of the biotech sector over the next half-decade.

Apr 28, 2014 at 6:30PM

Don't tell orphan drugmaker Alexion Pharmaceuticals (NASDAQ:ALXN) that the biotech sector's in a slump. This standout stock, best known for producing the most expensive drug in the world -- $400,000-per-year Soliris -- has outpaced the market handily so far in 2014. Year to date, Alexion's stock has jumped nearly 17%, crushing the Nasdaq Composite's (NASDAQINDEX:^IXIC) flat year so far and outpacing many of biotech's biggest names.

Yet investors need more than just past performance; it's pivotal that top-notch biotech firms come through with growing drug sales to paint a rosy future for the company. Alexion stepped up to bat on Wednesday with its first-quarter earnings, but did this company impress investors heading into the heart of 2014?

Orphan-drug heavyweight

Alexion

Source: Alexion.

High-priced orphan drugs used to treat rare and ultra-rare diseases have risen from market afterthoughts to investor gems. Alexion's own Soliris, used to treat a pair of rare blood disorders, has garnered at least 36% sales growth in each of the last two years and pulled in more than $1.5 billion in revenue in 2013. Alexion's not the only drugmaker showing off the potential of orphan drugs: Fellow orphan drug biotech leader Vertex Pharmaceuticals (NASDAQ:VRTX) has rallied behind the potential of Kalydeco, a cystic fibrosis treatment for select patient populations that pulled in more than $370 million last year and more than doubled 2012's revenue. Vertex's drug could emerge as a blockbuster in the coming years -- or even potentially a megablockbuster in the $5 billion annual sales range if Vertex expands Kalydeco's approved indications into larger cystic fibrosis patient pools.

With strong potential from Soliris, analysts had expected big things from Alexion going into its first-quarter earnings report. On average, Wall Street projected more than 95% year-over-year per-share earnings growth from the company, with revenue jumping 65.3% over 2013's first quarter. Given Soliris' rapid growth to among the elite drugs of the biotech sector, this hardly was out of reach for this strong company.

Not only hardly out of reach, it seems, but easily surpassed as well. Alexion thumped analyst projections by pulling in $1.53 in adjusted per-share earnings, and reeled in 67% year-over-year sales growth to beat on the top line as well. Along with a reduction of SG&A costs by 10%, those results pushed the company to raise its full-year profit outlook.

Investors sent Alexion's stock up 2.5%, but I think it still has room to run. Analysts project that Soliris could rack up more than $3 billion by 2018. Alexion has another five further indications for the drug currently under clinical development, according to its most recent pipeline update. If Soliris can expand to more patient populations, this drug could have a very bright future.

The company has more ammunition in its pipeline that should keep investors interested in its future. Hypophosphatasia drug asfotase alfa could launch in the U.S., Europe, and Japan next year, and peak sales for the drug could be north of $500 million.

Alexion's bright future
2014's been good to Alexion so far, but if the first quarter's any indication, this stock could keep on churning higher behind Soliris' success as the year progresses. Alexion's efforts to expand Soliris' indications could help this drug emerge as an even bigger hit in coming years, and if this company can diversify its product portfolio with asfotase alfa in the near future, and more drugs later on, Alexion investors could be poised to make big rewards.

 

Innovation: The best path to rich rewards in biotech
Alexion's become one of biotech's biggest smash hits recently. Looking for the next breakout technology in health care that could turn your portfolio into riches is critical to keep up growth momentum.
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

 

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers